Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lefradafiban and Clopidogrel Interaction in Healthy Males
NCT02265289Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 1999
- Primary completion
- Feb 1999
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of lefradafiban in thrombosis, sponsored by Boehringer Ingelheim. Primary endpoints: Inhibition of platelet aggregation in platelet rich plasma at 383.5 hours, Fibrinogen receptor occupancy levels at 383.5 hours and 3 more. Started Jan 1999; status: completed.
02
Drugs
lefradafiban
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT02265289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265289.